Evidence map›Paper›PMID 32529492›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Salivary biomarkers in breast cancer: a cross-sectional study.

Pía López-Jornet, Cristina Aznar, Jose Ceron, Tvarijonaviciute Asta

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Pía López-JornetFaculty of Medicine and Odontology, Hospital Morales Meseguer, Clínica Odontológica, Marqués del los Vélez s/n, 30008, Murcia, Spain. majornet@um.es.ORCID http://orcid.org/0000-0002-3314-8613
Cristina AznarFaculty of Medicine and Odontology, Hospital Morales Meseguer, Clínica Odontológica, Marqués del los Vélez s/n, 30008, Murcia, Spain.
Jose CeronInterdisciplinary Laboratory of Clinical Analysis Interlab-UMU, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, Murcia, Spain.
Tvarijonaviciute AstaInterdisciplinary Laboratory of Clinical Analysis Interlab-UMU, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, Murcia, Spain.
Hospital General Universitario Morales Meseguer · ESUniversidad de Murcia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe objective was to evaluate the diagnostic value of salivary biomarkers in breast cancer. MATERIALS AND

methodsA prospective study was carried out of 91 consecutive breast cancer patients and 60 controls without neoplastic disease. Demographic data were recorded, along with the Hospital Anxiety Depression (HAD), risk for development periodontal diseases questionnaire and Mini-Nutritional Assessment (MNA) scores, and the TNM classification and stage of the primary tumor. Unstimulated basal saliva samples were collected and stored at - 80 °C until analysis.

resultsThe mean salivary CA125 concentration was 102.1 pg/ml in the control group and 267.6 pg/ml in the breast cancer group (p = 0.005). The soluble Fas (sFas) concentration in turn was 84.1 pg/ml and 145.9 pg/ml, respectively (p = 0.008). None of the biomarkers was related to questionnaire-assessed risk for development of periodontal diseases. The area under the ROC curve was 0.68 for CA125 (95% CI, 0.05-0.56) and 0.67 for sFas (95% CI, 0.08-0.55).

conclusionsThe salivary biomarkers CA125 and sFas appear to be promising tools in the diagnosis of breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsCA-125 AntigenCase-Control StudiesCross-Sectional Studiesfas ReceptorFemaleHumansMembrane ProteinsMiddle AgedNeoplasm StagingProspective StudiesROC CurveSalivaBiomarkers, TumorCA-125 AntigenFAS protein, humanfas ReceptorMembrane ProteinsMUC16 protein, humanBreast cancerCA125Periodontal diseasesSalivary biomarkersSFas

Identifiers

PMID32529492
OpenAlexW3035712116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.